<DOC>
	<DOCNO>NCT00653614</DOCNO>
	<brief_summary>The study perform multi-center , randomize , double-blind , parallel-group trial fertile woman age 18 35 year inclusive . A total 600 volunteer randomize one six treatment group . The study perform Germany . The investigational drug oral contraceptive . It contain estrogen estradiol ( E2 ) progestogen drospirenone ( DRSP ) . As contraceptive efficacy yet prove new regimen , even protection unwanted pregnancy assure . The treatment apply daily 7 cycle 28 day without pill-free interval , i.e. , 196 consecutive day . Treatment initiate screen period approximately 1 2 week , latter focus confirmation baseline safety status . Tablet intake start first day first menstrual/withdrawal bleed Visit 2 , regardless whether volunteer first user ( starter ) switch another COC . In follow cycle , tablet intake trigger bleeding event . The primary objective study evaluate compare cycle control bleed pattern six different treatment regimen E2/DRSP administration 7 treatment cycle . Volunteers provide diary document intake study medication , bleed event , day without bleeding , pregnancy test result . Safety also assess . During whole study period , 4 visit plan . At Screening Final examination , thorough physical examination gynecological examination ( include breast palpation cervical smear ) perform . Blood sample take safety laboratory parameters.Additional examination perform time , becomes necessary medical reason . At Visit 3 case premature discontinuation study investigator discus option follow-up contraception volunteer . The volunteer start intake post-treatment OC day last tablet intake study medication , negative urine ÃŸ-HCG test ( home pregnancy test ) result .</brief_summary>
	<brief_title>Cycle Control Safety E2-DRSP</brief_title>
	<detailed_description />
	<mesh_term>Drospirenone</mesh_term>
	<criteria>Healthy female volunteer Age : 18 35 year ( inclusive ) , smoker must older 30 year inclusion History regular cyclic menstrual period ( cycle length 25 35 day ) Willingness use barrier method contraception ( condoms spermicide , diaphragms spermicide , spermicidal vaginal suppository ) abstinence trial Pregnancy , lactation ( less three menstrual cycle Visit 1 follow delivery , abortion , lactation ) Obesity ( BMI &gt; 30.0 kg/m2 ) Abnormal , suspicious unclear cervical smear ( cervical smear take Visit 1 normal result document within last 6 month Visit 1 ) Laboratory value outside inclusion range Screening Any disease may worsen hormonal treatment might interfere conduct study interpretation result , e.g . : Cardiovascular presence history venous arterial thrombotic/thromboembolic event ( e.g. , deep venous thrombosis , pulmonary embolism , myocardial infarction ) cerebrovascular accident , include prodromi ( e.g. , transient ischemic attack , angina pectoris ) condition could increase risk suffer mention disorder , e.g. , family history indicate hereditary predisposition . uncontrolled arterial hypertension ( repeat measurement systolic blood pressure &gt; 140 mmHg and/or diastolic blood pressure &gt; 90 mmHg ) Liver presence history liver tumor ( benign malignant ) presence history severe hepatic disease long liver function value return normal jaundice and/or pruritus related cholestasis history cholestatic jaundice associate pregnancy previous COC use Metabolic diseases uncontrolled diabetes mellitus vascular involvement severe dyslipoproteinemia Other disease : know suspect malignant premalignant disease , uncontrolled thyroid disorder , chronic inflammatory bowel disease , severe renal insufficiency acute renal failure , hemolytic uremic syndrome , sickle cell anemia , porphyria , history hypertriglyceridemiaassociated Pancreatitis , systemic lupus erythematodes , pemphigoid gestationis previous pregnancy , Sydenham chorea , herpes gestationis , otosclerosisrelated hearing loss , history migraine focal neurologic symptom , epilepsy , current history clinically significant depression , hereditary angioedema Additional sex steroid , hormonal contraceptive method ( oral , transdermal ) treatment ( blister use randomization finish ) ; intrauterine device ( IUD ) without hormone release within 1 month prior Visit 1 , implant within 1 month prior Visit 1 , depot progestin within 6 month prior Visit 1 Surgical intervention schedule study period</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Oral contraception</keyword>
</DOC>